Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners (Frazier) announced a collaboration to launch HilleVax, Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takedas norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan, in exchange for upfront consideration, as well as future cash milestones and royalties on net sales.
- Read more about Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/takeda-and-frazier-healthcare-partners-announce-collaboration-to-launch-hillevax-inc-to-develop-clinical-stage-norovirus-vaccine-candidate
No comments:
Post a Comment